Executive Medical Director, Global Medical Affairs, Neuroscience
Novartis UK
London, United Kingdom
Hybrid
Enterprise medical voice for asset
Strategic partner to r&d
Shape early portfolio
Acts as the enterprise medical voice for the asset or disease area across the lifecycle (early to in-market) and strategic partner to Research, Development, US and International TA, peri- and post-launch, ensuring MA input is reflected in the asset development plan
Job Summary
Acts as the enterprise medical voice for the asset or disease area across the lifecycle (early to in-market) and strategic partner to Research, Development, US and International TA, peri- and post-launch, ensuring MA input is reflected in the asset development plan.
The Executive Director is responsible for the implementation of medical strategies for early programs globally with focus on innovative evidence solutions including interventional studies, NIS and RWE studies and implementation science projects.
Partner with Development, S&G, US and International cross-functions to shape portfolio early and diversify evidence to achieve broad access at launch and to enhance impact on clinical practice for priority programs.
Matching Summary
Acts as the enterprise medical voice for the asset or disease area across the lifecycle (early to in-market) and strategic partner to Research, Development, US and International TA, peri- and post-launch, ensuring MA input is reflected in the asset development plan.